The GLOW Blend capitalizes on this principle through strategic integration of collagen synthesis enhancement (GHK-Cu via TGF- pathway activation), angiogenic signaling (BPC-157 through VEGFR2 upregulation and TB-500 via endothelial progenitor cell mobilization), anti-inflammatory modulation (coordinated NF-B suppression by all three peptides), and cytoskeletal organization (TB-500 actin sequestration enabling enhanced cellular responses to GHK-Cu and BPC-157 signaling), creating a comprehensive regenerative research tool for investigating fundamental questions about tissue repair, aging, and cellular plasticity in laboratory environments
The demonstrated activity of orally administered BPC-157 in gastrointestinal models confirms sufficient stability in gastric juice and resistance to complete enzymatic degradation during intestinal transit, at least for local mucosal effects if not systemic absorption
Saneyoshi T, Wayman G, Fortin D, Davare M, Hoshi N, Nozaki N, et al
The rationale for combining these peptides emerged from observations that they operate through overlapping yet distinct pathways BPC-157 excels at promoting angiogenesis and reducing inflammation, while TB-500 focuses on actin regulation and cellular migration to injury sites
